MA42130A - Combinaisons d'opioïdes et de n-acyléthanolamines - Google Patents
Combinaisons d'opioïdes et de n-acyléthanolaminesInfo
- Publication number
- MA42130A MA42130A MA042130A MA42130A MA42130A MA 42130 A MA42130 A MA 42130A MA 042130 A MA042130 A MA 042130A MA 42130 A MA42130 A MA 42130A MA 42130 A MA42130 A MA 42130A
- Authority
- MA
- Morocco
- Prior art keywords
- acylethanolamines
- opioids
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164618P | 2015-05-21 | 2015-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42130A true MA42130A (fr) | 2018-03-28 |
Family
ID=57319619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042130A MA42130A (fr) | 2015-05-21 | 2016-05-17 | Combinaisons d'opioïdes et de n-acyléthanolamines |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180116982A1 (fr) |
| EP (1) | EP3297622B1 (fr) |
| JP (2) | JP7244992B2 (fr) |
| CN (2) | CN116808038A (fr) |
| AU (4) | AU2016263292B2 (fr) |
| CA (1) | CA2985305C (fr) |
| DK (1) | DK3297622T3 (fr) |
| ES (1) | ES2968345T3 (fr) |
| IL (3) | IL322263A (fr) |
| MA (1) | MA42130A (fr) |
| PL (1) | PL3297622T3 (fr) |
| WO (1) | WO2016185468A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201802129QA (en) | 2017-07-05 | 2019-02-27 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| PH12018000227B1 (en) | 2017-09-05 | 2019-03-11 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of chronic kidney disease |
| US12590054B2 (en) * | 2021-12-23 | 2026-03-31 | Board Of Regents, The University Of Texas System | Use of D9-methadone for postoperative pain relief |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008355537B2 (en) * | 2008-04-28 | 2014-02-06 | 21 Holding Sas Di Monico Cav. Silvano | Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide |
| KR101773331B1 (ko) | 2012-03-05 | 2017-08-31 | 닥터 레디스 레보러터리즈 리미티드 | 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드 |
| US9656961B2 (en) | 2013-05-24 | 2017-05-23 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| TR201908936T4 (tr) * | 2014-05-14 | 2019-07-22 | Epitech Group S P A | Opioidler ile kombinasyon halinde palmitoiletanolamid kullanımı. |
-
2016
- 2016-05-17 JP JP2017559829A patent/JP7244992B2/ja active Active
- 2016-05-17 DK DK16796016.0T patent/DK3297622T3/da active
- 2016-05-17 EP EP16796016.0A patent/EP3297622B1/fr active Active
- 2016-05-17 CN CN202310348490.3A patent/CN116808038A/zh active Pending
- 2016-05-17 IL IL322263A patent/IL322263A/en unknown
- 2016-05-17 MA MA042130A patent/MA42130A/fr unknown
- 2016-05-17 CN CN201680032663.9A patent/CN107613966A/zh active Pending
- 2016-05-17 ES ES16796016T patent/ES2968345T3/es active Active
- 2016-05-17 US US15/575,655 patent/US20180116982A1/en not_active Abandoned
- 2016-05-17 IL IL305528A patent/IL305528B2/en unknown
- 2016-05-17 PL PL16796016.0T patent/PL3297622T3/pl unknown
- 2016-05-17 CA CA2985305A patent/CA2985305C/fr active Active
- 2016-05-17 AU AU2016263292A patent/AU2016263292B2/en active Active
- 2016-05-17 WO PCT/IL2016/050519 patent/WO2016185468A1/fr not_active Ceased
-
2017
- 2017-11-19 IL IL255749A patent/IL255749A/en unknown
-
2020
- 2020-11-27 US US17/105,687 patent/US20210177779A1/en active Pending
-
2021
- 2021-04-30 JP JP2021077846A patent/JP2021138703A/ja active Pending
- 2021-06-30 AU AU2021204517A patent/AU2021204517B2/en active Active
-
2023
- 2023-10-19 AU AU2023251499A patent/AU2023251499B2/en active Active
-
2025
- 2025-12-11 AU AU2025279727A patent/AU2025279727A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3297622A1 (fr) | 2018-03-28 |
| CN107613966A (zh) | 2018-01-19 |
| AU2021204517A1 (en) | 2021-07-29 |
| AU2023251499B2 (en) | 2025-09-25 |
| WO2016185468A1 (fr) | 2016-11-24 |
| EP3297622B1 (fr) | 2023-11-01 |
| EP3297622A4 (fr) | 2019-01-02 |
| PL3297622T3 (pl) | 2024-03-18 |
| AU2016263292B2 (en) | 2021-04-01 |
| JP7244992B2 (ja) | 2023-03-23 |
| ES2968345T3 (es) | 2024-05-09 |
| JP2021138703A (ja) | 2021-09-16 |
| IL305528A (en) | 2023-10-01 |
| CA2985305C (fr) | 2024-04-09 |
| CA2985305A1 (fr) | 2016-11-24 |
| JP2018515547A (ja) | 2018-06-14 |
| IL305528B2 (en) | 2026-01-01 |
| AU2023251499A1 (en) | 2023-11-09 |
| US20210177779A1 (en) | 2021-06-17 |
| IL255749A (en) | 2018-01-31 |
| IL305528B1 (en) | 2025-09-01 |
| CN116808038A (zh) | 2023-09-29 |
| AU2016263292A1 (en) | 2017-11-30 |
| AU2021204517B2 (en) | 2023-07-27 |
| IL322263A (en) | 2025-09-01 |
| US20180116982A1 (en) | 2018-05-03 |
| AU2025279727A1 (en) | 2026-01-15 |
| DK3297622T3 (da) | 2024-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3065470T3 (en) | Novel micro-dystrophins and related methods of use | |
| IL293377B1 (en) | Hsd17b13 variants and uses thereof | |
| IL285433A (en) | Converted tricycles and method of use | |
| IL259747A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| IL259495A (en) | Antibodies and methods for using them | |
| IL254039A0 (en) | Anti-pvrig antibodies and methods of use | |
| PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| IL254887A0 (en) | Anti-sortilin antibodies and methods of using them | |
| IL251972B (en) | Analyzing and utilizing landscapes | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| EP3800791C0 (fr) | Codeur et décodeur polaires activés par signature | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| EP4212536C0 (fr) | Composés de benzoxazepine oxazolidinone et procédés d'utilisation | |
| SG10201912150TA (en) | Anti-trem2 antibodies and methods of use thereof | |
| PT3215532T (pt) | Anticorpos anti-tim3 e métodos de utilização | |
| MA49715A (fr) | Oligomères et conjugués d'oligomères | |
| BR112018000129A2 (pt) | oxiesteróis e seus métodos de utilização | |
| IL270793A (en) | Anti-HTRA1 antibodies and methods of using them | |
| MA41997A (fr) | Combinaisons de cannabinoïdes et de n-acyléthanolamines | |
| PT3319612T (pt) | Oxisteróis e métodos de utilização dos mesmos | |
| BR112016020889A2 (pt) | variantes de hppd e métodos de uso | |
| EP3534910A4 (fr) | Procédés et agents thérapeutiques | |
| EP3398262A4 (fr) | Caractérisation et sélection de micro-routes | |
| EP3417845A4 (fr) | Composition de formation de alpha-gel et composition de alpha-gel |